Replies to post #19236 on Pluristem Therapeutics Inc (PSTI)

[Auto1]

Thanks for that, Jack. Something tells me you are WAY more of an expert than you are giving yourself credit for. You naturally have an MD's mindset it seems, IMO.

Maybe Buerger's Disease would have been the ticket. Taking the 'ultra-orphan' route in rare diseases has commanded drug prices of over $1M per patient/annually. Eleprase, etc. in the enzyme replacement market.

In the case of ALXN and PNH, TX cost is well north of 500K/PT/Year...

Coulda, Should, Would, but the 3D bet is yet to be covered.

I do fear the loss of any head-start in this space.

[zzaatt]

like I said, I’m no expert.

Don't worry, "Auto1" IS, AND he doesn't get "CONSULTING FEES"! LOL! and he thinks Pluristem is going after the WRONG indications!!! .... really!!! Maybe the company should hire "Auto1" as a ........ CONSULTANT (but no fees, PLEASE!) LOL!

Good presentation. One more small piece of data that corroborates the Pluristem story. Perhaps the implications of success in CLI can be broadened to include a multitude of occlusive diseases... hmm, maybe CLI is a pretty good indication to start with!

The money issue is something we have to look at, but my feeling is that as the evidence of efficacy keeps coming in, the ability of the company to raise funds will improve substantially. The challenge for Pluristem is no different than any other small biotech, success in the clinic will translate into support from partnerships, grants and other means. I don't think it should be a major worry.